Skip to main content

Day: February 22, 2021

International Money Express, Inc. Sees Its Co-Branded Service Realize Significant Growth

MIAMI, Feb. 22, 2021 (GLOBE NEWSWIRE) — International Money Express, Inc. (NASDAQ: IMXI), (Intermex) (the Company) a leading money remittance services company, announced its co-branded digital service marketed by Amigo Paisano, generated impressive triple-digit remittance growth in 2020. Although Amigo Paisano’s primary country is Guatemala, they also deliver the ability to send money to 17 other countries in LATAM, as does Intermex directly.Amigo Paisano develops unique and cost-effective marketing programs to reach and grow its digital money transfer service using the co-branded Intermex digital app, computer software, quality control, and delivery systems across the LATAM countries in which Intermex operates. The partnership helps expand Intermex’s reach and expertise in the LATAM digital marketplace and enables the Company to...

Continue reading

Global Boatwork Holdings, Inc. Appoints Two Criminal Justice Advocates to Board of Directors

Nationally Recognized Social and Criminal Justice Advocates, DeAnna R. Hoskins and Saad Soliman, Appointed  Independent DirectorsBALTIMORE MD, Feb. 22, 2021 (GLOBE NEWSWIRE) —  via NewMediaWire — Global Boatworks Holdings, Inc.(OTC: GBBT),  (“Global” or “the Company”) today announcedthat it has appointed DeAnna R. Hoskins and Saad Soliman to the Company’sboard of directors,effective  February 12, 2021. These appointments bring the Company’s total board membership to 5. “We are pleased to welcome both DeAnna Hoskins and Saad Soliman as new independent directors to the board,” said Laurin Leonard, R3 Holdings, Inc., CEO, and Co-Founder. “Both DeAnna and Saad have distinguished themselves as leading social and criminal justice reform advocates with deep policy expertise and insights gained from their years...

Continue reading

Myovant Sciences to Present at Upcoming Investor Conferences

BASEL, Switzerland, Feb. 22, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences:SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021 at 3:40 p.m. Eastern Time. David Marek, Chief Executive Officer of Myovant Sciences, Inc., and Frank Karbe, President and Chief Financial Officer of Myovant Sciences, Inc., will participate in a fireside chat. Management will also participate in one-on-one investor meetings on February 25.Cowen 41st Annual Health Care Conference on March 2, 2021 at 11:10 a.m. Eastern Time. Mr. Marek and Mr. Karbe will participate in a fireside chat. Management will also participate in one-on-one investor meetings on March...

Continue reading

PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing COVID-19 Vaccine

FLORHAM PARK, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, and Farmacore Biotechnology today announced that Blanver Farmoquímica e Farmacêutica S.A. has joined their consortium to develop and commercialize a novel COVID-19 vaccine in Latin America.Blanver is a leading Brazilian Pharmaceutical Company focused on the development, manufacture, and commercialization of innovative pharmaceutical products. Under the terms of the agreement, São Paulo-based Blanver will manufacture, promote, distribute, and commercialize the Versamune®-based COVID-19 vaccine in Latin America. As the license holder of Versamune-CoV2-FC (PDS0203)...

Continue reading

Vericel to Present at the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the SVB Leerink 10th Annual Global Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Thursday, February 25, 2021, at 10:00 a.m. Eastern Time.A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.About Vericel CorporationVericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured...

Continue reading

Diana Shipping Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2020

ATHENS, Greece, Feb. 22, 2021 (GLOBE NEWSWIRE) — Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership of dry bulk vessels, today reported a net loss of $7.4 million and net loss attributed to common stockholders of $8.9 million for the fourth quarter of 2020, including a $1.9 million impairment loss. This compares to a net loss of $14.0 million and net loss attributed to common stockholders of $15.4 million reported in the fourth quarter of 2019, including a $6.5 million impairment loss and $3.3 million loss on sale of vessels.Time charter revenues were $42.7 million for the fourth quarter of 2020, compared to $51.5 million for the same quarter of 2019. The decrease in time charter revenues was mainly due to the decrease in ownership days resulting from the sale of two vessels in...

Continue reading

Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference

HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 2:20 p.m. ET.A webcast of the presentation will be available on the “Events & Presentations” page of the “Investors & Media” section of the Celldex website. A replay will be available for fourteen days following the event.About Celldex Therapeutics, Inc.Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system...

Continue reading

Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

Company AnnouncementCOPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Operating Officer Anthony Mancini.Based in Genmab’s New Jersey, U.S. office, Dr. Ahmadi has been instrumental in the scale up of the fully integrated R&D...

Continue reading

SurgePays Adds Jay Jones, Seasoned Telecom and Software Development Executive, to its Board of Directors

BARTLETT, Tenn., Feb. 22, 2021 (GLOBE NEWSWIRE) — SurgePays, Inc. (OTCQB: SURG) (“SurgePays” or the “Company”), a fintech company building a next generation supply chain network that can offer wholesale goods and financial services for the underbanked more cost efficiently than traditional distribution models, announces today that Jjkareem (Jay) Jones, a telecom and software development executive with over 30 years of experience, has joined the Company’s Board of Directors.“Jay brings a wealth of hands-on and executive experience in the telecom industry that will be a tremendous asset to us as we aggressively roll out our nationwide wireless LocoRabbit services through the thousands of convenience stores and mini-marts that are the epicenters of the underbanked communities,” said SurgePays CEO and Chairman Brian Cox. “With both...

Continue reading

Kevin Diamond Joins PLBY Group as Chief Digital Officer

LOS ANGELES, Feb. 22, 2021 (GLOBE NEWSWIRE) — PLBY Group, Inc. (NASDAQ: PLBY) (the “Company”), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most recognizable and iconic brands in the world, today announced the appointment of Kevin Diamond to newly created role of Chief Digital Officer, reporting directly to Ben Kohn, Chief Executive Officer. In his new role, which begins on February 24, 2021, Mr. Diamond will be responsible for expanding PLBY Group’s global digital commerce business, elevating the Company’s global digital experience, and strengthening its technology infrastructure underpinning.Mr. Diamond joins PLBY Group from Forever 21, where he served as the Head of Global E-Commerce, responsible for the company’s more than $700 million global digital commerce business, its product and technology...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.